Abstract 70P
Background
The safety and efficacy of intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct plus laparoscopic cholecystectomy (ENBD+ LC+ LCBD) for cholecystolithiasis combined with common bile duct stones (CBD stones) are uncertain.
Methods
The meta-analysis search was performed using PUBMED, OVID, EMBASE, and Cochrane database. All studies comparing ENBD+ LC+ LCBD and ECRP/EST+ LC from 1990 to 2018 were included. Pooled effect was calculated using the fixed and random effects models when necessary.
Results
A total of 5 trails included 700 patients with two different treatments (ENBD+ LC+ LCBD and ECRP/EST+ LC) were identified. The ENBD+ LC+ LCBD group had less total complications or adverse events (RR = 0.268, 95% CI:0.138–0.520, I2=0.0%, P < 0.001). And subgroup analysis of total complications exposed that although ENBD+ LC+ LCBD group developed more of biliary leak, there was no significance (RR = 3.890, 95% CI:0.88–17.25, I2=0.0%, P = 0.074). Meanwhile, there were lower rates of retained stones (RR = 0.272, 95% CI:0.09–0.85, I2=0.0%, P = 0.026), postoperative bleeding (RR = 0.129, 95% CI:0.02–0.75, I2=0.0%, P = 0.022) and pancreatitis (RR = 0.127, 95% CI:(0.04–0.43, I2=0.0%, P = 0.001) in ENBD+ LC+ LCBD group. Although operative time (WMD=32.465, 95% CI:0.468–64.61, I2=98.6%, P = 0.047) showed significant difference, sensitivity analysis didn’t confirm the robustness of the results. Futhermore, it seemed that ENBD+ LC+ LCBD group had a shorter length of postoperative hospital stay (WMD=-1.880, 95% CI:-3.063–-0.696, I2=94.4%, P = 0.002) and less expenditure of hospitalization (WMD=-430.439, 95% CI:-704.620–-156.258, I2=92.3%, P = 0.002).
Conclusions
It is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for patients with cholecystolithiasis combined with CBD stones.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai.
Funding
Opening Fund of Engineering Research Center of Cognitive Healthcare of Zhejiang Province (No.2018KFJJ09).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract